About Gilead Sciences, Inc.
Gilead Sciences, Inc. (GILD) has been publicly traded since 1992, making it a 34-year-old public company. It operates in the Drug Manufacturers - General industry within the Healthcare sector. The company is headquartered in Foster City, United States and employs approximately 17,000 people. With a market capitalization of $180 billion, GILD is a large established company.
Key Statistics
- Current Price
- $146.02
- Market Cap
- $181.27B
- 52-Week High
- $157.29
- 52-Week Low
- $93.37
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
$1,000 Invested
Monthly Returns Heatmap
Annual Returns
| Year | Return | Start | End |
|---|---|---|---|
| 2026 | +18.96% | $122.74 | $146.02 |
| 2025 | +36.59% | $89.86 | $122.74 |
| 2024 | +18.68% | $75.71 | $89.86 |
| 2023 | -1.99% | $77.25 | $75.71 |
| 2022 | +23.63% | $62.49 | $77.25 |
| 2021 | +29.95% | $48.08 | $62.49 |
| 2020 | -6.70% | $51.54 | $48.08 |
| 2019 | +7.88% | $47.77 | $51.54 |
| 2018 | -9.92% | $53.03 | $47.77 |
| 2017 | +2.96% | $51.51 | $53.03 |
| 2016 | -27.59% | $71.14 | $51.51 |
| 2015 | +8.63% | $65.49 | $71.14 |
| 2014 | +25.51% | $52.18 | $65.49 |
| 2013 | +104.49% | $25.51 | $52.18 |
| 2012 | +79.45% | $14.22 | $25.51 |
| 2011 | +12.94% | $12.59 | $14.22 |
| 2010 | -16.25% | $15.03 | $12.59 |
| 2009 | -15.39% | $17.76 | $15.03 |
| 2008 | +11.15% | $15.98 | $17.76 |
| 2007 | +41.72% | $11.28 | $15.98 |
| 2006 | +23.51% | $9.13 | $11.28 |
| 2005 | +50.24% | $6.08 | $9.13 |
| 2004 | +20.08% | $5.06 | $6.08 |
| 2003 | +71.41% | $2.95 | $5.06 |
| 2002 | +3.47% | $2.85 | $2.95 |
| 2001 | +58.48% | $1.80 | $2.85 |
| 2000 | +53.23% | $1.18 | $1.80 |
| 1999 | +31.81% | $0.89 | $1.18 |
| 1998 | +7.35% | $0.83 | $0.89 |
| 1997 | +53.00% | $0.54 | $0.83 |
| 1996 | -21.88% | $0.69 | $0.54 |
| 1995 | +236.84% | $0.21 | $0.69 |
| 1994 | -20.83% | $0.26 | $0.21 |
| 1993 | -37.66% | $0.42 | $0.26 |
Valuation
GILD currently trades at a trailing P/E ratio of 21.4, which is considered moderate relative to the broader market. The forward P/E of 15.1 suggests analysts expect earnings to be lower in the coming year. The price-to-book ratio stands at 7.9. The price-to-sales ratio is 6.1.
Dividends
Gilead Sciences, Inc. pays a dividend to shareholders with a current yield of 2.26%. This translates to $3.28 per share annually. The payout ratio of 47% indicates sustainable dividend coverage.
Risk & Volatility
GILD has a beta of 0.37, indicating it is less volatile than the overall market. The stock's 52-week range is $93.37 to $157.29, and it currently trades near its 52-week high.
Analyst Ratings
Based on 28 analyst opinions, GILD has a consensus "buy" rating. The average price target of $157.43 suggests 8.6% upside from current levels.
Frequently Asked Questions
What does Gilead Sciences, Inc. do? ▼
Gilead Sciences, Inc. is a Drug Manufacturers - General company operating in the Healthcare sector. The company is headquartered in Foster City, United States.
What sector is GILD in? ▼
GILD operates in the Healthcare sector, specifically in the Drug Manufacturers - General industry.
When did GILD go public? ▼
Gilead Sciences, Inc. went public in 1992, making it a 34-year-old public company as of 2026.
How much would $1,000 invested in GILD 5 years ago be worth today? ▼
A $1,000 investment in GILD five years ago would be worth approximately $2,750 today, representing a 175.0% return.
Does GILD pay dividends? ▼
Yes, Gilead Sciences, Inc. pays a dividend with a current yield of 2.26%, which is $3.28 per share annually.
What is GILD's market cap? ▼
Gilead Sciences, Inc. has a market capitalization of $180 billion, classifying it as a large-cap company.
What is GILD's P/E ratio? ▼
GILD has a trailing P/E ratio of 21.4 and a forward P/E of 15.1, which measures how much investors are paying per dollar of earnings.
Is GILD a buy, hold, or sell? ▼
Based on 28 opinions, GILD has a consensus "buy" rating. The average price target is $157.43.
Last updated: 3/14/2026